SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-21-000067
Filing Date
2021-01-07
Accepted
2021-01-07 07:02:07
Documents
14
Period of Report
2021-01-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20210107x8k.htm   iXBRL 8-K 40599
2 EX-99.1 kala-20210107xex99d1.htm EX-99.1 17919
3 GRAPHIC kala-20210107xex99d1001.jpg GRAPHIC 3227
  Complete submission text file 0001558370-21-000067.txt   197317

Data Files

Seq Description Document Type Size
4 EX-101.SCH kala-20210107.xsd EX-101.SCH 3028
5 EX-101.LAB kala-20210107_lab.xml EX-101.LAB 16735
6 EX-101.PRE kala-20210107_pre.xml EX-101.PRE 10607
7 EXTRACTED XBRL INSTANCE DOCUMENT kala-20210107x8k_htm.xml XML 5011
Mailing Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 781-996-5252
Kala Pharmaceuticals, Inc. (Filer) CIK: 0001479419 (see all company filings)

IRS No.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 21512972
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences